These findings correspond to the findings with Remsima.[29] This is important because the costs of IBD treatment are mainly driven by first and second generation anti-TNF- α agents, and biosimilars are generally much cheaper.[9] As a result of the specificity of biosimilars, IBD patients without antibodies against Infliximab could in theory be treated with or switched to a cheaper biosimilar. Here, TNF is linked to inflammatory bowel disease.